Please use this identifier to cite or link to this item:
https://ir.swu.ac.th/jspui/handle/123456789/14111
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chittasupho C. | |
dc.contributor.author | Jaturanpinyo M. | |
dc.contributor.author | Mangmool S. | |
dc.date.accessioned | 2021-04-05T03:33:12Z | - |
dc.date.available | 2021-04-05T03:33:12Z | - |
dc.date.issued | 2013 | |
dc.identifier.issn | 10717544 | |
dc.identifier.other | 2-s2.0-84872251182 | |
dc.identifier.uri | https://ir.swu.ac.th/jspui/handle/123456789/14111 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84872251182&doi=10.3109%2f10717544.2012.739214&partnerID=40&md5=c83dd3b9068374e9736d4da81ef1e914 | |
dc.description.abstract | Objective: This work has aimed to develop methotrexate-conjugated pectin nanoparticle for delivering a cytotoxic drug to hepatic cancer cell. Methods: Methotrexate was conjugated to pectin by carbodiimide chemistry. Nanoparticles of pectin conjugated with methotrexate (MTX) were then fabricated by using ionotropic gelation. The size, shape and surface charge were characterized by dynamic light scattering and microscopic method. Cytotoxicity of MTX-pectin nanoparticle was monitored by MTT assay. Results: Methotrexate-pectin nanoparticle was successfully formulated. Drug release study indicated that MTX-NP exhibited sustained drug release at pH 7.4. Sustained release of methotrexate may enable methotrexate-pectin nanoparticle as a controlled drug delivery system. Cytotoxicity study confirmed the activity of the drug incorporated in nanoparticles. In addition, the cytotoxicity of methotrexate was increased when conjugated to pectin nanoparticles, compared to free methotrexate. Conclusions: This study verified that pectin can deliver methotrexate to hepatic cancer cell and provide sustained drug delivery. The cytotoxicity of methotrexate was enhanced when methotrexate was conjugated to pectin indicating the improved drug delivery to cancer cell. © 2013 Informa Healthcare USA, Inc. | |
dc.subject | methotrexate | |
dc.subject | nanoparticle | |
dc.subject | pectin | |
dc.subject | article | |
dc.subject | cancer cell culture | |
dc.subject | cytotoxicity | |
dc.subject | drug delivery system | |
dc.subject | drug release | |
dc.subject | drug structure | |
dc.subject | human | |
dc.subject | human cell | |
dc.subject | in vitro study | |
dc.subject | liver cancer | |
dc.subject | pH measurement | |
dc.subject | priority journal | |
dc.subject | Antimetabolites, Antineoplastic | |
dc.subject | Cytotoxins | |
dc.subject | Drug Delivery Systems | |
dc.subject | Hep G2 Cells | |
dc.subject | Humans | |
dc.subject | Methotrexate | |
dc.subject | Nanoparticles | |
dc.subject | Pectins | |
dc.title | Pectin nanoparticle enhances cytotoxicity of methotrexate against hepG2 cells | |
dc.type | Article | |
dc.rights.holder | Scopus | |
dc.identifier.bibliograpycitation | Drug Delivery. Vol 20, No.1 (2013), p.1-9 | |
dc.identifier.doi | 10.3109/10717544.2012.739214 | |
Appears in Collections: | Scopus 1983-2021 |
Files in This Item:
There are no files associated with this item.
Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.